NCT06517953招募中2 期
A Phase II Study to Assess Befotertinib and Icotinib as First-Line Treatment in Patients With Locally Advanced or Metastatic NSCLC and Uncommon EGFR Mutation(IcomBine, GASTO-10114)
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2024年7月17日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- Objective Response Rate （ORR）
研究概览
简要总结
This research study aims to explore the combination of two targeted drugs as first-line treatment for Non-Small Cell Lung Cancer (NSCLC) with uncommon EGFR mutation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age or older.
- •Pathologically confirmed adenocarcinoma of the lung, with locally advanced or metastatic disease and not amenable to curative surgery or radiotherapy (stage IIIB, IIIC or IV disease based on the eighth edition of the American Joint Committee on Cancer (AJCC) TNM classification). Patients with mixed histology are eligible if adenocarcinoma is the predominant histology.
- •Patients must be treatment-naive for locally advanced or metastatic NSCLC systemic antitumor therapy. Prior adjuvant and neo-adjuvant therapy (except for EGFR-TKIs) is permitted if have been completed at least 6 months prior to initiation of disease progression.
- •Tissue or blood samples are confirmed by the central laboratory or research center as rare EGFR mutations, including exon 18 G719X, S768I in exon 20 and at least one of the L861Q mutations in exon 21;
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to
- •Predicted survival ≥ 3 months.
- •At least 1 measurable tumor lesion without radiotherapy as per RECIST v1.
- •Agree to use effective contraception during the study period and for at least 3 months after completion of the study treatment.
- •Provision of informed consent prior to any study procedure.
排除标准
- •Combined with other malignancy(except for clinically cured in situ cervix carcinoma, basal cell or squamous epithelial skin cancer,thyroid papillary carcinoma).
- •Prior treatment with any EGFR-TKIs.
- •Prior treatment with any systemic antitumor therapy for locally advanced or metastatic NSCLC.
- •Previous traditional chinese medicine with an antitumor indication within 2 weeks before the first dose of study drug.
- •Previous major surgery within 4 weeks before the first dose of study drug,or planing to have major surgery during study.
- •Symptoms or signs worsened within 2 weeks before the first dose of study drug.
- •Any unresolved toxicities from prior treatment greater than NCI CTCAE v4.03 grade 2 or higher.
- •Spinal cord compression,symptomatic or unstable central nervous system (CNS) metastases that require the use of steroids .Patients who have a stable CNS status for at least 4 weeks before treatment will be allowed to join the study.
- •Any clinical evidence of serious or uncontrolled systemic disease,including uncontrolled hypertension after drug treatment,active bleeding diatheses, previous or present thrombus,uncontrolled cardiovascular and cerebrovascular diseases.
- •Active infection including hepatitis B,hepatitis C,syphilis and human immunodeficiency virus (HIV).
- •Mean resting corrected QT interval (QTcF) ≥450 msec,obtained from 3 ECGs or any clinically important abnormalities in rhythm,conduction, morphology of resting ECG or left ventricular ejection fraction (LVEF) ≤ 50%,etc.
- •Previous history of interstitial lung disease(ILD),drug-induced interstitial lung disease,history of radiation-induced pneumonia requiring hormone therapy,or clinical evidence of active interstitial lung disease.
- •Any instance that affects the patient's ability to swallow drug or oral malabsorption.
- •Occur any laboratory indicator abnormalities as follow：
- •absolute neutrophil count(ANC)<1,500/mcL
- •platelets<100,000/mcL
- •hemoglobin<9.0 g/dL
- •AST/ALT>2.5 times the upper limit of normal (ULN)or >5 times the ULN in the presence of liver metastases
- •total bilirubin(TBIL)>1.5 times the ULN if no liver metastases or > 3 times the ULN in the presence of liver metastases
- •serum creatinine(SCr) >1.5 times the ULN or creatinine clearance ≥50 mL/min.
- •Patients with a known allergy or delayed hypersensitivity reaction to the any component of study drugs or their excipients.
- •Within 1 week before the first dose of study drug currently receiving or need concomitant medications known to be potent inhibitors or inducers of CYP3A, CYP2D6,CYPC8 and CYP2C19,sensitive substrate of CYP3A and CYP2C
- •Within 1 week before the first dose of study drug ongoing use of warfarin.
- •Previous therapeutic clinical trial within 4 weeks before the first dose of study drug.
研究组 & 干预措施
Icotinib + Befotertinib
Experimental
orally Icotinib 125mg Tid plus orally Befotertinib 100mg qd until progression disease
干预措施: Icotinib (Drug)
Icotinib + Befotertinib
Experimental
orally Icotinib 125mg Tid plus orally Befotertinib 100mg qd until progression disease
干预措施: Befotertinib (Drug)
结局指标
主要结局
Objective Response Rate （ORR）
时间窗: 24 months
ORR, per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as complete response (CR) or partial response (PR).
次要结局
- Progression-free survival（PFS）(12 months)
- Disease control rate（DCR）(12 months)
- Overall survival （OS）(24 months)
研究者
Xue Hou
Principal Investigator
Sun Yet-Sen University Cancer Center
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung CancerNon-Small Cell Lung CancerNCT05007938Betta Pharmaceuticals Co., Ltd.30
进行中（未招募）
2 期
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerNon-small Cell Lung CancerNCT03392246Dana-Farber Cancer Institute25
进行中（未招募）
2 期
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT02629809M.D. Anderson Cancer Center81
Unknown
2 期
Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790MNon Small Cell Lung CancerNCT04029350Tianjin Medical University Cancer Institute and Hospital53
Unknown
2 期
A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung AdenocarcinomaCarcinoma, Non-Small-Cell LungNCT02146118MedicalLogic42